Paul Peter Tak
Paul Peter Tak is a business leader, academic, entrepreneur and clinician who has over 30 years’ experience in medicine as a prominent expert in Immunology, Internal Medicine, and Rheumatology. Paul Peter is currently the President, CEO, and Board Director of Candel Therapeutics, the Co-Founder and Board Director of Sitryx Therapeutics, Board Director of Levicept and Chair of Citryll.
Alongside his industry career, Paul Peter has dedicated much of his life to academia and advancing our understanding in medicine. He has served as Professor of Medicine at the University of Amsterdam and holds numerous honours for his service to medicine, with a special focus on Immunology and Rheumatology.
Extended follow-up data from our phase 3 trial of aglatimagene besadenovec (CAN-2409) in localized prostate cancer will be presented at #AUA2026 in Washington, D.C.
https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-new-data-after-extended-follow
@AmerUrological #AUA2026 #ProstateCancer #Immunotherapy $CADL
On #WorldHealthDay, we reaffirm our commitment to the power of science to transform cancer care.
At Candel, we’re advancing a pipeline of multimodal viral immunotherapies designed to harness the immune system to fight cancer and bring new options within reach for patients.
@TargetedOnc covered our latest aglatimagene besadenovec (CAN-2409) data in ICI-resistant advanced NSCLC: 50% alive at 24 months, 35% at 30 months, 13% beyond 50 months. Persistence of a long-term survival tail in this difficult-to-treat population.
https://www.targetedonc.com/view/aglatimagene-besadenovec-shows-durable-survival-in-ici-refractory-nsclc
Pleased to share this important milestone for the Kennedy Trust for Rheumatology Research and the Kennedy Institute of Rheumatology at the University of Oxford.
A major new five-year funding commitment of £28 million will extend our longstanding partnership through 2031,
